Koyfin Home > Directory > Health Care > Acorda Therapeutics > EV / EBITDA (ltm)

Acorda Therapeutics EV / EBITDA (ltm) Chart (ACOR)

Acorda Therapeutics annual/quarterly EV / EBITDA (ltm) from 2011 to 2019. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the last twelve months (LTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Acorda Therapeutics EV / EBITDA (ltm) for the quarter ending July 07, 2019 was 5.69 a 1.95% increase of 0.11 year over year
  • Acorda Therapeutics EV / EBITDA (ltm) for the last 12 months ending July 07, 2019 was 5.69 a 1.95% increase of 0.11 year over year
  • Acorda Therapeutics Annual EV / EBITDA (ltm) for 2019 was 5.69 a -1.04% decrease of -0.06 from 2018
  • Acorda Therapeutics Annual EV / EBITDA (ltm) for 2019 was 5.75 a 1.93% increase of 0.11 from 2018
  • Acorda Therapeutics Annual EV / EBITDA (ltm) for 2019 was 5.64 a 1.05% increase of 0.06 from 2018
Other Valuation Metrics:
  • Acorda Therapeutics Market Cap for the quarter ending March 03, 2018 was $1,110m a 17.15% increase of 190m year over year
  • Acorda Therapeutics Price / Book for the quarter ending March 03, 2018 was 2.11 a 35.48% increase of 0.75 year over year
  • Acorda Therapeutics Enterprise Value for the quarter ending March 03, 2018 was $1,138m a 2.19% increase of 25m year over year
View Chart On Koyfin

Quarterly ACOR EV / EBITDA (ltm) Data

07/20195.69
07/20195.75
07/20195.64
07/20195.58
07/20195.58
07/20195.61
07/20195.56
07/20195.43
07/20195.67
07/20195.66

Annual ACOR EV / EBITDA (ltm) Data

20195.69
20195.75
20195.64
20195.58
20195.58
20195.61
20195.56
20195.43
20195.67
20195.66